Complement C5 Inhibition for Immune-Mediated Necrotizing Myopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds and therapeutic methods to address complement-related inflammation and associated pathologies, particularly in neuromuscular inflammatory indications such as Immune-Mediated Necrotizing Myopathy (IMNM), which are characterized by muscle weakness, chronic inflammation, and elevated serum creatine kinase levels.
Innovation Solution
Administration of a complement inhibitor, such as zilucoplan, a synthetic macrocyclic peptide that binds complement component 5 (C5) with sub-nanomolar affinity, to inhibit its cleavage and reduce complement-mediated self-tissue destruction, combined with therapeutic agents like rituximab, steroids, or immunosuppressive therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If complement inhibitors are administered to treat IMNM, then muscle strength and function improve, but the complexity of the therapeutic regimen increases
Solution Approach 1:
The patent introduces complement inhibitors (eculizumab, ravulizumab, zilucoplan) as intermediary substances that specifically target and inhibit the complement system's harmful effects on muscle tissue. These inhibitors act as mediators between the immune system and muscle tissue, blocking C5 convertase from cleaving C5 into C5a and C5b, thereby preventing MAC formation and muscle cell destruction while allowing other therapeutic agents to address different aspects of the disease
Solution Approach 2:
The patent changes the therapeutic parameter from general immunosuppression to specific complement inhibition. By targeting the complement system's terminal pathway (C5 conversion), the treatment shifts from broad immune suppression to precise modulation of the harmful complement-mediated muscle destruction pathway, improving efficacy while allowing for more targeted and potentially less complex long-term management
2Reliability
If complement inhibitors are used to reduce self-tissue destruction, then muscle function improves, but treatment cost and accessibility may worsen
Solution Approach 1:
The patent describes complement inhibitors as relatively short-acting therapeutic agents that require repeated administration (every 2 weeks to monthly for ravulizumab and zilucoplan, every 4 weeks for eculizumab). This disposable approach allows for flexible dosing and potential cost management strategies, where the therapeutic effect is achieved through periodic rather than permanent treatment, improving accessibility compared to lifelong complex regimens
3Object-affected harmful factors
If C5 cleavage is inhibited to prevent MAC formation, then muscle tissue protection improves, but pathogen destruction capability may worsen
Solution Approach 1:
The patent exploits the local quality difference between pathological and physiological complement activation. In IMNM, complement activation is localized to muscle tissue causing destruction, whereas in normal immunity, complement activation occurs at pathogen sites. By administering C5 inhibitors systemically, the drug concentrates at sites of active complement activation (muscle tissue in IMNM), protecting vulnerable tissue while allowing complement-mediated pathogen destruction to occur at infection sites where pathogens express complement regulatory proteins that protect host cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces serum creatine kinase levels and improves muscle strength and function in subjects with IMNM, as evidenced by improvements in muscle contraction and clinical assessment scores.
Implementation Method 1
zilucoplan, a synthetic macrocyclic peptide that binds complement component 5 (C5) with sub-nanomolar affinity, to inhibit its cleavage
Data Source
AI summary
The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods of treating neuromuscular inflammatory indications, such as Immune-Mediated Necrotizing Myopathy.